Management of restless legs syndrome by the partial D2-agonist terguride.
BACKGROUND
Terguride as a partial D2-receptors agonist seems suitable for treatment of restless legs syndrome (RLS).


METHODS
Nine RLS patients without previous dopaminergic therapy received a daily dose of terguride (0.25 mg) 29.9+/-16.9 (SD) days.


RESULTS
Two patients enrolled in the study failed to turn up for a successive check up. The seven subjects who were re-examined complied with the therapy. Their RLS symptoms improved (as measured on the International RLS intensity scale), decreasing from 24.3+/-5.3 to 14+/-4.7 (p=0.014). However, the terguride treatment did not significantly alter the daytime sleepiness or the subjective duration of nocturnal sleep. The daily dose was doubled in three patients who reported insufficient RLS improvement. One of the three patients later reported augmentation.
Sonka
Karel
K
Department of Neurology, First Medical Faculty, Charles University, Katerinska 30, 12000 Prague 2, Czech Republic. ksonka@lf1.cuni.cz
Pretl
Martin
M
Kranda
Karel
K
D000328:Adult; D000368:Aged; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008090:Lisuride / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017448:Receptors, Dopamine D2 / Q000819:agonists*; D012148:Restless Legs Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D012647:Self-Assessment; D012890:Sleep; D012894:Sleep Stages / Q000187:drug effects; D016896:Treatment Outcome
D018491:Dopamine Agonists; D017448:Receptors, Dopamine D2; C006208:dironyl; D008090:Lisuride